Australia - English - Department of Health (Therapeutic Goods Administration)

ferring pharmaceuticals pty ltd - triptorelin acetate, quantity: 100 microgram (equivalent: triptorelin, qty 95.6 microgram/ml) - injection, solution - excipient ingredients: glacial acetic acid; water for injections; sodium chloride - decapeptyl 100 micrograms/1 ml is indicated for down-regulation and prevention of premature luteinising hormone (lh) surges in women undergoing controlled ovarian hyperstimulation for assisted reproductive technologies (art).,in clinical trials decapeptyl 100 micrograms/1 ml has been used in cycles where urinary and recombinant human follicle stimulating hormone (fsh) as well as human menopausal gonadotrophin (hmg) were used for stimulation.

Australia - English - Department of Health (Therapeutic Goods Administration)

ferring pharmaceuticals pty ltd - somatropin -

Australia - English - Department of Health (Therapeutic Goods Administration)

ferring pharmaceuticals pty ltd - desmopressin, quantity: 240 microgram (equivalent: desmopressin acetate, qty 272 microgram) - wafer - excipient ingredients: mannitol; citric acid; gelatin - 1- cranial diabetes insipidus. 2- primary nocturnal enuresis in patients from 6 years of age with normal ability to concentrate urine who are refractory to an enuresis alarm or in whom the enuresis alarm is contraindicated or inappropriate.

Australia - English - Department of Health (Therapeutic Goods Administration)

ferring pharmaceuticals pty ltd - desmopressin, quantity: 120 microgram (equivalent: desmopressin acetate, qty 136 microgram) - wafer - excipient ingredients: citric acid; mannitol; gelatin - 1- cranial diabetes insipidus. 2- primary nocturnal enuresis in patients from 6 years of age with normal ability to concentrate urine who are refractory to an enuresis alarm or in whom the enuresis alarm is contraindicated or inappropriate.

Australia - English - Department of Health (Therapeutic Goods Administration)

ferring pharmaceuticals pty ltd - progesterone, quantity: 100 mg - pessary, compressed - excipient ingredients: lactose monohydrate; pregelatinised maize starch; magnesium stearate; povidone; adipic acid; sodium lauryl sulfate; colloidal anhydrous silica; sodium bicarbonate - endometrin pessaries are indicated for luteal support as part of an assisted reproductive technology (art) treatment programme for infertile women.

Australia - English - Department of Health (Therapeutic Goods Administration)

ferring pharmaceuticals pty ltd - mesalazine, quantity: 1000 mg - suppository, compressed - excipient ingredients: purified talc; povidone; macrogol 6000; magnesium stearate - treatment of ulcerative procitis.

Australia - English - Department of Health (Therapeutic Goods Administration)

ferring pharmaceuticals pty ltd - mesalazine, quantity: 1000 mg - enema - excipient ingredients: disodium edetate; sodium acetate; purified water; sodium metabisulfite; hydrochloric acid - for the treatment of ulcerative proctosigmoiditis and/or treatment of left-sided ulcerative colitis.

Australia - English - Department of Health (Therapeutic Goods Administration)

ferring pharmaceuticals pty ltd - desmopressin acetate, quantity: 0.1 mg/ml (equivalent: desmopressin, qty 0.089 mg/ml) - spray, solution - excipient ingredients: dibasic sodium phosphate dihydrate; citric acid monohydrate; sodium chloride; purified water; benzalkonium chloride - diabetes insipidus:the treatment of adh-sensitive cranial diabetes insipidus, including treatment of post-hypophysectomy polydipsia and polyuria.,nocturnal enuresis: minirin nasal spray is indicated for the symptomatic treatment of primary nocturnal enuresis in patients who have normal ability to concentrate urine. minirin nasal spray should be used only in patients who are refractory to the enuresis alarm or in patients in whom enuresis alarm is contraindicated or inappropriate, and where the oral administration of desmopressin is not feasible.,renal concentrating capacity: by intranasal administration to adults and children as a diagnostic test to establish renal concentrating capacity.

Australia - English - Department of Health (Therapeutic Goods Administration)

ferring pharmaceuticals pty ltd - quinagolide hydrochloride -

Australia - English - Department of Health (Therapeutic Goods Administration)

ferring pharmaceuticals pty ltd - quinagolide hydrochloride, quantity: 0.0819 mg (equivalent: quinagolide hydrochloride, qty 75 microgram) - tablet, uncoated - excipient ingredients: colloidal anhydrous silica; magnesium stearate; hypromellose; maize starch; microcrystalline cellulose; lactose monohydrate - hyperprolactinaemia (idiopathic or originating from a prolactin- secreting pituitary microadenoma or macroadenoma) associated with its clinical manifestations such as galactorrhoea, oligomenorrhoea, amenorrhoea, infertility and reduced libido.